Finanzen von Autolus Therapeutics PLC (AUTL)AUTLAutolus Therapeutics PLC

Evaluating the bottom line, Autolus Therapeutics PLC maintains a gross margin of 57.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -86.33%, while the net margin is -85.60%. These profitability ratios, combined with a Return on Equity (ROE) of -133.00%, provide a clear picture of how effectively AUTL converts its operational activities into shareholder value.

In the context of the broader market, AUTL competes directly with industry leaders such as MPLT and OVID. With a market capitalization of $420.54M, it holds a significant position in the sector. When comparing efficiency, AUTL's gross margin of 57.61% stands against MPLT's N/A and OVID's 100.00%. Such benchmarking helps identify whether Autolus Therapeutics PLC is trading at a premium or discount relative to its financial performance.

Autolus reported a revenue of $45.69 million in Q2 2026, reflecting a 119% year-over-year growth, and has raised its full-year revenue guidance to between $140 million and $150 million.